KRAS

Across TCGA pan-cancer cohorts, KRAS mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated KRAS data layer compared with 24 for mass-spec protein and 14 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher KRAS mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated KRAS expression acts as an unfavorable survival marker, although some lineages such as GBM and CCRCC show a favorable association.

PDAC, GBM, and LUAD are the cancer types where KRAS mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Quartile	III,IV	0.196	0.704	.002	18	view →
GBM	DFS	Tertile	All	0.872	0.618	.002	16	view →
LUAD	OS	Tertile	III,IV	0.373	0.734	.013	13	view →
CCRCC	DFS	Tertile	All	0.883	0.434	.017	8	view →
HNSC	OS	Median	II,III,IV	1.000	0.956	.031	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

KRAS–PDAC (OS)

Open the PDAC breakdown →